Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening—United States, 2016

Authors

Katherine Fay
Olivia Almendares
Barbara Robinson-Dunn, Beaumont Health
Stephanie Schrag

Document Type

Article

Publication Date

6-1-2019

Publication Title

Diagnostic Microbiology and Infectious Disease

Abstract

© 2018 Elsevier Inc. Perinatal group B Streptococcus (GBS) disease prevention guidelines in 2010 allowed for processing of screening specimens by nucleic acid amplification tests (NAATs); however, the extent of NAAT use is unknown. A 2016 laboratory survey sent to 10 surveillance sites found that 18.7% of responding laboratories offered NAAT for GBS screening (antenatal only: 7.3%; intrapartum only: 4.1%; both: 3.4%).

Volume

94

Issue

2

First Page

157

Last Page

159

Recommended Citation

Fay K, Almendares O, Robinson-Dunn B, Schrag S. Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening-United States, 2016. Diagn Microbiol Infect Dis. 2019 Jun;94(2):157-159. doi: 10.1016/j.diagmicrobio.2018.11.026. Epub 2018 Dec 11. PMID: 30642719.

DOI

10.1016/j.diagmicrobio.2018.11.026

ISSN

07328893

PubMed ID

30642719